Fluorouracil and other predictors of morpheaform basal cell carcinoma among high-risk patients: the Veterans Affairs Topical Tretinoin Chemoprevention Trial

JAMA Dermatol. 2014 Mar;150(3):332-4. doi: 10.1001/jamadermatol.2013.5619.

Veterans Affairs Topical Tretinoin Chemoprevention Trial Group:
Martin A Weinstock, Kimberly Marcolivio, Martin A Weinstock, Stephen Bingham, John J DiGiovanna, Russell Hall, Mark Naylor, J Richard Taylor, Julia Vertrees, Clifton White, Russell Hall, Deborah Hannah, David Eilers, Tehming Liang, Nadia Sakla, Ann Kreuger, Gary Cole, Edward Jeffes, Terri Labrador, J Richard Taylor, Robert Kirsner, Jonette E Kerri, Anna G Falabella, Margarita Givens, Mark Naylor, Mary Beth Benson, Lisa Perry, James Kalivas, Catherine Yanni, Selma Targovnik, Janet Austin, Susan Collier, Joseph F Collins, Stephen Bingham, Beverly Calvert, Philip Connor, Colleen Crigler, Dawn Davis, Pat Grubb, Judy Kelly, Gail Kirk, Karen Lawson, Linda Linzy, Lorrine Palmer, Maxine Rhoads, Mike Sather, Erica Copeland, Carol Fye, William Gagne, Patricia Grimes de Naranjo, Chad Messick, and Julia Vertrees, Michael Piepkorn, Clifton White, Robert Lew, Irwin Braverman, Richard Kalish, David McLean, Bruce Harris Thiers

¹ Dermatoepidemiology Unit, VA Medical Center, Providence, Rhode Island2Department of Dermatology, Warren Alpert Medical School of Brown University, Providence, Rhode Island.
² DNA Repair Section, Dermatology Branch, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, Maryland.
³ Dermatoepidemiology Unit, VA Medical Center, Providence, Rhode Island2Department of Dermatology, Warren Alpert Medical School of Brown University, Providence, Rhode Island4Department of Dermatology, Rhode Island Hospital, Providence5Department of Epidemio.

No abstract available

Publication types